A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways
- Conditions
- Healthy Volunteer
- Interventions
- Registration Number
- NCT06741657
- Lead Sponsor
- Biogen
- Brief Summary
In this study, researchers will learn how the body processes litifilimab when it is given under the skin in 3 different ways. Currently, ongoing studies utilize pre-filled syringes (PFS) that can deliver litifilimab subcutaneously (SC), also known as under the skin.
In this study, researchers want to learn more about new ways of delivering litifilimab SC using either an autoinjector (AI) or an on-body injector (OBI):
Both devices are designed to deliver litifilimab in an automatic way, especially helping patients who may not be able to use their hands very well, or who may be afraid of needles. While the AI is handheld, the OBI device works by being placed on the skin and can help deliver the highest amount of litifilimab through a single injection. The main objective of this study is to learn how the body processes litifilimab after using the AI device or the OBI device, as compared to using the PFS method.
The main questions researchers want to answer are:
* What is the highest amount of litifilimab found in the blood after dosing? How much total litifilimab is found in the blood throughout the study? Researchers will also learn more about: Any medical problems the participants have during the study
* Any injection site pain or reactions the participants may have. Any skin reactions to the OBI device
* Any changes in the participants' overall health after receiving litifilimab.
This study will be done as follows:
* Participants will be screened to check if they can join the study. The screening period will be up to 4 weeks, after which selected participants will check into their study research center.
* Participants will be randomly assigned to be in Part 1 or Part 2 of the study:
* Part 1: Participants will receive SC injection(s) of litifilimab through either the AI device or through PFS.
* Part 2: Participants will receive SC injection(s) of litifilimab through the OBI device or through PFS.
* Participants will remain at their study research center for the first 8 days. After that, there will be a follow-up period for 17 weeks during which participants return to the center a total of 6 times.
Each participant will be in the study for about 22 weeks.
- Detailed Description
The primary objective of this study is to assess the pharmacokinetic (PK) comparability of litifilimab administered via SC injection(s) of AI (Test Device 1) or SC injection(s) of OBI (Test Device 2), with SC injections of PFS (Reference) in healthy participants.
The secondary objectives of this study are to evaluate the safety and tolerability following SC dose of litifilimab via AI, OBI, or PFS; to assess additional PK parameters following SC dose of litifilimab via AI, OBI, or PFS in healthy participants.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 236
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Part 2: OBI versus PFS Litifilimab Participants will receive SC dose of litifilimab injection via OBI or PFS on Day 1 of the study. Part 1: AI versus PFS Litifilimab Participants will receive SC dose of litifilimab injection via AI or PFS on Day 1 of the study. Part 1: AI versus PFS AI Participants will receive SC dose of litifilimab injection via AI or PFS on Day 1 of the study. Part 1: AI versus PFS PFS Participants will receive SC dose of litifilimab injection via AI or PFS on Day 1 of the study. Part 2: OBI versus PFS OBI Participants will receive SC dose of litifilimab injection via OBI or PFS on Day 1 of the study. Part 2: OBI versus PFS PFS Participants will receive SC dose of litifilimab injection via OBI or PFS on Day 1 of the study.
- Primary Outcome Measures
Name Time Method Part 1 and 2: Maximum Observed Concentration (Cmax) of Litifilimab Pre-dose and at multiple timepoints up to Week 22 Part 1 and 2: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) Pre-dose and at multiple timepoints up to Week 22
- Secondary Outcome Measures
Name Time Method Part 1 and 2: Volume of Distribution (Vd/F) of Litifilimab Pre-dose and at multiple timepoints up to Week 22 Part 1 and 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) From screening up to Week 22 Part 1 and 2: Change From Baseline in the Injection Site Pain as Measured by Patient Reported Outcome (PRO) Using a Pain Intensity Numeric Rating Scale (PI-NRS) Baseline, Day 1 A PI-NRS scale will be used to assess overall injection site pain at different time points. The scale ranges from 0 to 10 where '0' indicates 'no pain' and '7-10' indicates 'severe pain'.
Part 1 and 2: Percentage of Participants With Mild, Moderate, Severe, or no Injection Site Reactions Up to Week 1 Part 2: Percentage of Participants With Adhesive Contact Skin Reactions as Measured by Dermal Response and Other Effects Scales Up to Week 1 A dermal response scale will be used to assess the adhesive contact skin reactions. The scale ranges from 0 to 7, where '0' indicates 'no evidence of irritation' and '7' indicates 'strong reaction spreading beyond the application site'. The other effects scale ranges from 'A(0)' to 'H(3)', where a 'A(0)' indicates a slightly glazed appearance and 'H(3)' indicates small petechial erosions and/or scabs.
Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant Vital Signs Abnormalities Baseline, up to Week 22 Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant 12-Lead Electrocardiograms (ECGs) Abnormalities Baseline, up to Week 4 Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant Laboratory Evaluation Abnormalities Baseline, up to Week 22 Part 1 and 2: Number of Participants With Change From Baseline in Clinically Significant Physical Examination Abnormalities Baseline, up to Week 22 Part 1 and 2: Time to Reach Cmax (Tmax) of Litifilimab Pre-dose and at multiple timepoints up to Week 22 Part 1 and 2: Terminal Elimination Half-life (t1/2) of Litifilimab Pre-dose and at multiple timepoints up to Week 22 Part 1 and 2: Apparent Total Clearance (CL/F) of Litifilimab Pre-dose and at multiple timepoints up to Week 22 Part 1 and 2: Area Under the Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Litifilimab Pre-dose and at multiple timepoints up to Week 22
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (2)
Las Vegas Clinical Research Unit
🇺🇸Las Vegas, Nevada, United States
Austin Clinical Research Unit
🇺🇸Austin, Texas, United States